

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2003240761 B2**

(54) Title
OX4OR binding agents

(51) International Patent Classification(s)
C07K 14/52 (2006.01) **A61P 37/00** (2006.01)
A61P 31/00 (2006.01) **C12N 15/28** (2006.01)
A61P 35/00 (2006.01) **A61K 38/00** (2006.01)

(21) Application No: **2003240761** (22) Date of Filing: **2003.04.02**

(87) WIPO No: **WO03/082919**

(30) Priority Data

(31) Number	(32) Date	(33) Country
02100334.8	2002.04.03	EP

(43) Publication Date: **2003.10.13**

(43) Publication Journal Date: **2003.11.20**

(44) Accepted Journal Date: **2009.04.23**

(71) Applicant(s)
Merck Serono SA

(72) Inventor(s)
Pena Rossi, Claudia;Soto Jara, Claudio

(74) Agent / Attorney
Griffith Hack, Level 3 509 St Kilda Road, Melbourne, VIC, 3004

(56) Related Art
Database GSP [Online] 12 February 2001 Rosen C. A. et al database Accession No. AAB44733 XP002211958 & WO 2000/58494 A (Human Genome Science Inc.) 5 October 2000.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 2003/082919 A3

(51) International Patent Classification⁷: **C07K 14/52**,
14/705, C12N 15/28, 5/10, 15/63, G01N 33/53, A61K
38/00, A61P 31/00, 35/00, 37/00

(21) International Application Number:
PCT/EP2003/050089

(22) International Filing Date: 2 April 2003 (02.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02100334.8 3 April 2002 (03.04.2002) EP

(71) Applicant (*for all designated States except US*): **AP-
PLIED RESEARCH SYSTEMS ARS HOLDING N.V.**
[NL/NL]; Pietermaai 15, Curaçao (AN).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SOTO JARA, Clau-
dio** [CL/CH]; Chemin des Cherpines 11, CH-1228 Plan-
les-Ouates (CH). **PENA ROSSI, Claudia** [AR/CH]; Rue
Emile Yung 8, CH-1205 Geneva (CH).

(74) Agent: **SERONO INTERNATIONAL S.A. INTEL-
LECTUAL PROPERTY**; 12, Chemin des Aulx, CH-1228
Plan-les-Ouates (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
5 February 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: OX40R BINDING AGENTS

(57) Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.



WO 2003/082919 A3

NOVEL OX40R BINDING AGENTS**FIELD OF THE INVENTION**

The present invention concerns novel peptides capable of modulating OX40
5 Receptor - OX40 Ligand interactions.

BACKGROUND OF THE INVENTION

The cell regulatory system constituted by the membrane proteins OX40 Receptor
(indicated in the literature also as OX40R, OX-40, OX-40 Antigen, TNFRSF4, or
10 CD134) and OX40 Ligand (indicated in the literature also as OX40L, glycoprotein gp34,
ACT-4-L, TNFSF4, CD134 Ligand, or CD134L) has a prominent role in the regulation
of immune responses as well as in the formation of secondary lymphoid tissue,
similarly to other proteins belonging to the tumor necrosis factor ligand / receptor
superfamilies (Gravestien L and Borst J, 1998; Weinberg A, 2002). Many evidences on
15 these activities have been provided by clinical observations and by animal models, for
example by gene targeting experiments (Chen A et al., 1999; Kopf M et al., 1999;
Murata K et al., 2000).

OX40 Receptor (OX40R, from now on) is a cell surface antigen, member of
TNFR family, transiently expressed following T cell receptor (TCR) engagement and
20 acting as a co-stimulatory receptor. It is considered as a highly specific CD4⁺ or CD8⁺
activation marker for T cells, being often over-expressed in inflammation sites
associated to immunological pathologies, such as in multiple sclerosis or rheumatoid
arthritis, as well as in tumor-infiltrating lymphocytes and in the peripheral blood of
animal models of graft-versus host disease.

OX40 Ligand (OX40L, from now on) is a transmembrane protein, originally identified as a protein stimulated by human T cell lymphotropic virus 1 infection and CD40 activation (Miura S et al., 1991), having structural similarity to TNF and capable of forming cell-bound or secreted trimers. It is present on activated, antigen-presenting
5 B and T cells, as well as dendritic cells, vascular endothelium cells and other non-hematopoietic tissues (for example heart, skeletal muscle, and pancreas).

OX40L interacts with OX40R as a homotrimer with a high affinity ($K_d = 0.2-0.4$ nM), and various binding assays have been tested on this system (Taylor L et al, 2002; Taylor L and Schwartz H, 2001; Al-Shamkhani A et al., 1997). However, no
10 tridimensional structure has been solved so far, neither detailed structure-activity studies have been performed, in order to provide any further molecular details on the mechanism of OX40L-OX40R interaction.

The interaction between OX40L and OX40R has a co-stimulatory effect to OX40R-expressing effector T cells, leading to a more robust cell responses due to the
15 up-regulation of the cytokine production by T helper cells (Th1 and Th2) and to an increased survival of memory T cells through the inhibition of activation-induced cell death. Confirming evidences were also obtained in the transgenic mice lacking a functional OX40L gene and in autoimmunity animal models, where it was demonstrated that blocking the OX40R-OX40L interaction or depleting OX40R-positive T cells
20 reduces clinical signs of autoimmunity.

Moreover, OX40L induces, upon OX40R binding, the expression of several genes, including the C-C chemokine RANTES, confirming the results obtained in endothelium models where OX40R-OX40L system appears involved in the control of activated T cells extravasation (Kotani A et al., 2002).

Cumulatively, these expression and functional data raise the possibility that the signal transduction pathways regulated by OX40L-OX40R interactions may help to prolong antigen-specific proliferative responses or otherwise influence the persistence, differentiation or reactivation of effector / memory T cell populations.

5 The interest on OX40R-OX40L system is related to the fact that, even if the intracellular signaling mechanisms have not yet completely understood, the expression profile of OX40R makes this protein a peculiar target for CD4⁺ T cells mediated diseases in clinical settings, for example in multiple sclerosis, where it is necessary to delete auto-reactive T cells. The hypothesis is that the products modulating OX40R
10 activity may not have the serious side effects of conventional immunosuppressive therapies for autoimmune diseases and transplant rejection, which target all T cells.

 The therapeutic potential of modulating the interaction between OX40L and OX40R was recognized by *in vivo* generated results obtained with OX40L-targeted immunotoxins (Weinberg A et al., 1996), anti-OX40R antibodies (Bansal-Pakala P et al., 2001), anti-OX40L antibodies (Stuber E and Strober W, 1996; Yoshioka Y et al.,
15 al., 2000; Tsukada N et al., 2000), and OX40L-Ig fusion proteins (Higgins LM et al., 1999; Weinberg A et al., 1999). These compounds are intended either to antagonize OX40L-OX40R interaction (for preventing the accumulation of activated CD4⁺ T cells at inflammatory sites) or to activate OX40R (as in some other pathological conditions,
20 such as cancer).

 Various OX40R binding agent, being either agonist or antagonist of OX40R, have been disclosed in the prior art as having positive effects on immunization and cancer treatment (WO 95/21915; WO 95/21251; EP 978287; WO 99/42585; WO 02/66044; US 6312700). However, only large molecule such as the OX40L whole extracellular

domain or antibodies are actually disclosed as being effective OX40R binding agents. This is also due to the fact that no real structure-activity studies have been performed to characterize this interaction, neither reliable information can be inferred from the analysis of other TNF / TNFR protein structures (Bodmer JL et al., 2002).

5 Since known OX40R binding agents proved to be useful as therapeutic and diagnostic agents, it would be desirable to identify compounds which, maintaining the binding and OX40L-competing properties of the large molecules above mentioned, are easier to generate and formulate such as peptides or other small molecules.

10 SUMMARY OF THE INVENTION

It has now been discovered that specific peptides derived from the extracellular domain of OX40L can be used as OX40R binding agents. More specifically, it has been found that a peptide corresponding to amino acids 94-124 of human OX40L, as well as fragments of this peptide comprising amino acids 107-116 of human OX40L, interact
15 with human OX40R with high affinity, as shown by two different reliable screening technologies. Such peptides, heterologous proteins comprising their sequences, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for different therapeutic uses. Other features and advantages of the invention will be apparent from the following
20 detailed description.

DESCRIPTION OF THE FIGURES

Figure 1: experimental design of the Alphascreen™ assay initially developed for demonstrating the feasibility of this approach for studying OX40L-OX40R interaction.

5 Figure 2: dose-dependent binding of OX40L-CD8 to OX40R-IgG₁ as detected using the Alphascreen™ assay. (A) Increasing concentrations of OX40L-CD8 were incubated with OX40R-IgG₁ at the concentration of 5 nM (○) or 10 nM (●) for 30 minutes. Biotinylated anti-CD8 antibody (10 nM) was then added and 30 minutes later, streptavidin donor (20 mg/ml) and protein A acceptor
10 (20 mg/ml) beads were added. One hour after these additions, the plate was counted on a Fusion™ reader. Only a very weak signal was detected in the absence of OX40R-IgG₁ (■). (B) Effect of increasing OX40R-IgG₁ concentration on Signal/Background (S/B) ratio. The S/B ratio was calculated by dividing counts obtained in the presence of OX40L-CD8 (100
15 nM) by background counts (in the absence of OX40L-CD8). Data are expressed as mean ± SEM (Standard Error of the Mean) and all experiments were performed 3 times in triplicate.

Figure 3: K_D determination of OX40L-CD8 for OX40R-IgG₁. OX40R-IgG₁ (10 nM) was incubated in the presence of increasing concentrations of OX40L-CD8. Specific binding (□) was calculated as the difference between total binding
20 (■) and non-specific binding (●) determined in the presence of Suramin (1 mM). Data are expressed as mean ± SEM from 3 experiments performed in triplicate.

Figure 4: Competition for OX40L-CD8 binding by OX40L and suramin. OX40-IgG (10 nM), OX40L-CD8 (40 nM) and increasing concentrations of soluble OX40L (●) or suramin (○) were incubated for 30 minutes prior to the addition of biotinylated anti-CD8 antibody (10 nM). Thirty minutes later streptavidin donor and protein A acceptor beads were added. The graph represents the percentage inhibition of the maximal Alphascreen™ signal (obtained in the absence of any inhibitor). Data are expressed as mean $\pm$ SEM from 3 experiments performed in triplicate

Figure 5: binding of OX40L fragments to OX40R-IgG₁. (A) sequence of human OX40L (SWISSPROT Acc. No. P23510), with the indication of the position of main protein domains (on the top of the sequence), together with the sequences corresponding to the peptides tested by the Alphascreen™-based competition assay or the mouse OX40L-derived peptides P-OX-1 and P-OX-2 (on the bottom of the sequence; non-identical amino acids are indicated). (B) inhibition of binding of OX40R-IgG₁ to OX40L-CD8 by the peptides P4, P5, and a control without any peptide.

Figure 6: binding of P5-derived peptides to OX40R-IgG₁ (A) sequence of peptide P5, aligned with mouse OX40L-derived peptide P-OX-1 (Stuber E and Strober W, 1996; indicates non conservative substitution and . indicates conservative substitutions, as indicated in Table I) and with the sequence of the P5-derived peptides tested with the Alphascreen™-based competition assay. The peptide P5-1a is the boxed sequence in P5-1. (B) Inhibition of binding of OX40R-IgG₁ to OX40L-CD8 by the peptide P5-1 in the

AlphascreenTM-based competition assay, compared with the effect provided by other fragments of peptide P5.

Figure 7: OX40R-IgG₁ interaction with peptides P5 (A) and P5-1 (B), as measured by using fluorescence quenching spectroscopy. Non-linear regression analysis of OX40R-IgG₁ fluorescence changes reveals a saturable binding with the dissociation constant for the OX40R-IgG₁ - peptide complex indicated as K_d value for the two peptides.

DETAILED DESCRIPTION OF THE INVENTION

All references, including any patents or patent application, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art, in Australia or in any other country.

In the claims of this application and in the description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

7a

In view of the evidences disclosed in the prior art, there is no indication of a specific peptide sequence into OX40L extracellular domain that would be useful as OX40R binding agent for inhibiting OX40R-OX40L interaction.

By screening series of peptides derived from OX40L extracellular domain, short
5 amino acid sequences that interact with OX40R with high affinity and compete with OX40L, were surprisingly identified and characterized as inhibitors of OX40R-OX40L interaction.

Accordingly, the present invention discloses a novel OX40R binding agent which is the peptide sequence corresponding to amino acids 94-124 (P5; SEQ ID NO: 6) of
10 human OX40L.

The present invention discloses OX40R binding agents which are peptide sequences of human OX40L consisting of a peptide sequence corresponding to amino acids 94-124 (peptide P5; SEQ ID NO: 6) wherein one or more amino acids have been deleted, and comprising amino acids 107-111 (peptide P5-1a; SEQ ID NO: 13) of
15 human OX40L. In particular these peptides have between 5 and 10 amino acids, and,

more in particular, have the sequence corresponding to amino acids 107-116 (peptide P5-1; SEQ NO ID: 8), or 107-111 (peptide P5-1a; SEQ ID NO: 13) of human OX40L.

The peptide P5, as well as the P5 fragments above defined, has been shown (or inferred) to bind human OX40R protein in the examples of the present patent application. This binding activity has been tested using *in vitro* assays employing recombinant forms of OX40L and OX40R, and demonstrating that OX40L can be effectively competed by the claimed peptide sequences. Novel means for inhibiting undesirable OX40R-OX40L interactions and cell signaling associated to human diseases are therefore provided by the present invention.

Fragments of the extracellular domain of human ACT-4-L, which is an alternative name of OX40L, were disclosed as potential OX40R binding agents being associated to functional or structural domains in the extracellular domain of OX40L (WO 95/21915). However, no evidence has been provided in the literature on functional or structural domains of human OX40L corresponding to peptide P5, or to its fragments such as the peptides P5-1 and P5-1a, as having competing activities towards OX40L. Peptides designed on the mouse OX40L extracellular domain sequence have been used as antigens for generating anti-OX40L antibodies (Stuber E and Strober W, 1996), but, also in view of the limited conservation of mouse and human OX40L in this region (figs. 5A and 6A), it cannot be inferred that any of these sequences can efficiently compete human OX40L for the binding to human OX40R.

The present patent application successfully demonstrates that, even if no functional or structural domain can be unequivocally predicted by comparing other ligand-receptor pairs belonging to the same protein families (Bodmer JL et al., 2002), or by using well-known algorithms for protein structure prediction such as PREDATOR,

PHD or HNN (accessible, for example, at http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_server.html), such peptides are surprisingly effective as OX40R binding agents capable of inhibiting OX40R-OX40L interaction.

5 The term "peptide" is ordinarily applied to a polypeptidic chain containing from 4 to 40 or more contiguous amino acids, usually from 4 to 20 contiguous amino acids. Such peptides can be generated by methods known to those skilled in the art, including partial proteolytic cleavage of a larger protein, chemical synthesis, or genetic engineering.

10 The term "active" defines the compound showing the OX40R binding properties demonstrated for the peptides of the present invention.

The properties of the peptide P5 and of its specific fragments exemplified by peptides P5-1 and P5-1a can be maintained, or even potentiated, in their active mutants. This category of molecules includes analogs of these sequences wherein one or more amino acid residues have been conservatively substituted, provided they
15 display the same biological activity characterized in the present invention at comparable or even higher levels, as determined by means known in the art or disclosed in the Examples below.

In accordance with the present invention, preferred changes in these active mutants are commonly known as "conservative" or "safe" substitutions. Conservative
20 amino acid substitutions are those with amino acids having sufficiently similar chemical properties, in order to preserve the structure and the biological function of the molecule. It is clear that insertions and deletions of amino acids may also be made in the above defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, e.g., under ten, and preferably under three,

and do not remove or displace amino acids which are critical to the functional conformation of a protein or a peptide.

The literature provide many models on which the selection of conservative amino acids substitutions can be performed on the basis of statistical and physico-chemical studies on the sequence and/or the structure of natural protein (Rogov SI and Nekrasov AN, 2001). Protein design experiments have shown that the use of specific subsets of amino acids can produce foldable and active proteins, helping in the classification of amino acid "synonymous" substitutions which can be more easily accommodated in protein structure (Murphy LR et al., 2000). The synonymous amino acid groups and more preferred synonymous groups are those defined in Table I.

These alternative compounds are intended to comprehend molecules with changes to the selected sequences of human OX40L which do not affect the basic characteristics disclosed in the present patent application, particularly insofar as its ability of binding and inhibiting OX40R is concerned. Similar compounds may result from conventional site-directed mutagenesis technique of the encoding DNA, from combinatorial technologies at the level of encoding DNA sequence (such as DNA shuffling, phage display/selection) or of amino acids, from computer-aided design studies, or any other known technique suitable thereof, which provide a finite set of substantially corresponding mutated peptides which can be routinely obtained and tested by one of ordinary skill in the art using the teachings presented in the prior art and in the Examples of the present patent application.

The present patent application discloses novel OX40 binding agents being fusion polypeptides or peptides comprising the amino acid sequence P5, P5-1, P5-1a, or any of their active mutants as defined above, and an amino acid sequence belonging to a

protein sequence other than human OX40L. This heterologous latter sequence should provide additional properties without considerably impairing OX40R binding activity. Examples of such additional properties are an easier purification procedure, a longer lasting half-life in body fluids, or extracellular localization. This latter feature is of particular importance for defining a specific group of fusion or chimeric proteins included in the above definition since it allows the peptides characterized as OX40R binding agent in this patent application to be localized in the space where not only where the isolation and purification of these peptides is facilitated, but also where OX40L and OX40R naturally interact.

Additional protein sequences which can be comprised in fusion proteins including the OX40R binding agent of the Invention can be chosen amongst membrane-bound proteins, extracellular domains of membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins.

The choice of one or more of these sequences to be fused to the OX40 binding agent is functional to specific use of said agent. As a general procedure, these fusion proteins can be produced by generating nucleic acid segments encoding them, using common genetic engineering techniques, and cloning in replicable vector of viral or plasmid origin which are used to modify a Prokaryotic or Eukaryotic host cell, using episomal or non-/homologously integrated vectors, as well as transformation-, infection-, or transfection-based technologies. These vectors should allow the expression of the fusion protein including the OX40R binding agent in the prokaryotic or eukaryotic host cell under the control of their own transcriptional initiation/termination regulatory sequences, which are chosen to be constitutively active or inducible in said

cell. A cell line substantially enriched in such cells can be then isolated to provide a stable cell line. In particular, whenever the cells modified to express the OX40R binding agents of the invention are directly used or administered, preferred cells are human cells normally expressing OX40L, in particular human B cells.

5 When the additional protein sequence, as in the case of the sequence of extracellular, export signal, or signal-peptide containing proteins, allows the OX40R binding domain to be secreted in the extracellular space, the agent can be more easily collected and purified from cultured cells in view of further processing or, alternatively, the cells can be directly used or administered.

10 When the additional protein, as in the case of the sequence of membrane-bound proteins, allows the immobilization of the OX40R binding agent on the surface of the cell, the agent can be less easily collected and purified from the cultured cells in view of further processing but the cells can be directly used or administered providing the agent in a form corresponding to the one of natural OX40L, possibly improving its
15 properties.

 Finally, since OX40L-OX40R interaction is known to involve multimerization of the proteins, in particular the trimerization (Al Shamkhani A et al., 1997). Therefore, the fusion protein may also include sequence allowing the multimerization of the resulting protein, such as the immunoglobulin constant regions, extracellular domains of
20 membrane-bound proteins, or trimerization domains known in the art as being present in TNFR-like (WO 00/39295) or in other proteins (WO 01/49866, WO 99/10510, WO 01/98507). Other useful protein sequences that can be included are the ones providing means of purification by affinity chromatography (Constans A, 2002; Lowe CR et al., 2001).

The polypeptides and the peptides of the present invention can be in alternative forms which can be preferred according to the desired method of use and/or production, for example as active fractions, precursors, salts, or derivatives.

The term "fraction" refers to any fragment of the polypeptidic chain of the compound itself, alone or in combination with related molecules or residues bound to it, for example residues of sugars or phosphates, or aggregates of the original polypeptide or peptide. Such molecules can result also from other modifications which do not normally alter primary sequence, for example *in vivo* or *in vitro* chemical derivativization of peptides (acetylation or carboxylation), those made by modifying the pattern of phosphorylation (introduction of phosphotyrosine, phosphoserine, or phosphothreonine residues) or glycosylation (by exposing the peptide to enzymes which affect glycosylation e.g., mammalian glycosylating or deglycosylating enzymes) of a peptide during its synthesis and processing or in further processing steps. For example, P5 and P5-1 contain a potential glycosylation site (amino acids 114-116 in human OX40L) and this can be modified accordingly during the recombinant expression in the host cell or during chemical synthesis.

The "precursors" are compounds which can be converted into the compounds of present invention by metabolic and enzymatic processing prior or after the administration to the cells or to the body.

The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the peptides, polypeptides, or analogs thereof, of the present invention. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines,

such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Any of such salts should have substantially similar activity to
5 the peptides and polypeptides of the invention or their analogs.

The term "derivatives" as herein used refers to derivatives which can be prepared from the functional groups present on the lateral chains of the amino acid moieties or on the N-/ or C-terminal groups according to known methods. Such derivatives include for example esters or aliphatic amides of the carboxyl-groups and N-acyl derivatives of
10 free amino groups or O-acyl derivatives of free hydroxyl-groups and are formed with acyl-groups as for example alcanoyl- or aroyl-groups.

Another object of the present invention are novel OX40R binding agents consisting of peptide mimetics (also called peptidomimetics) of the peptides P5, its specific fragments exemplified by peptides P5-1 and p5-1a, the corresponding active
15 mutants as defined above, in which the nature of peptide or polypeptide has been chemically modified at the level of amino acid side chains, amino acid chirality, and/or peptide backbone. These alterations are intended to provide OX40R binding agents having similar (if not improved) therapeutic, diagnostic and/or pharmacokinetic properties.

20 For example, when the peptide is susceptible to cleavage by peptidases following injection into the subject is a problem, replacement of a particularly sensitive peptide bond with a non-cleavable peptide mimetic can provide a peptide more stable and thus more useful as a therapeutic. Similarly, the replacement of an L-amino acid residue is a standard way of rendering the peptide less sensitive to proteolysis, and finally more

similar to organic compounds other than peptides. Also useful are amino-terminal blocking groups such as t-butyloxycarbonyl, acetyl, theyl, succinyl, methoxysuccinyl, suberyl, adipyl, azelayl, dansyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl, methoxyazelayl, methoxyadipyl, methoxysuberyl, and 2,4-dinitrophenyl. Many other
5 modifications providing increased potency, prolonged activity, easiness of purification, and/or increased half-life are known in the art (WO 02/10195; Villain M et al., 2001). Preferred alternative, "synonymous" groups for amino acids included in peptide mimetics are those defined in Table II.

The techniques for the synthesis and the development of peptide mimetics, as
10 well as non-peptide mimetics, are well known in the art (Sawyer TK, 1997; Hruby VJ and Balse PM, 2000; Golebiowski A et al., 2001; Kim HO and Kahn M, 2000). Various methodology for incorporating unnatural amino acids into proteins, using both *in vitro* and *in vivo* translation systems, to probe and/or improve protein structure and function are also disclosed in the literature (Dougherty DA, 2000).

15 Novel OX40R binding agents can be peptides, peptide mimetics, or non-peptide mimetics identified by methods of computer-aided drug design which make use of the structure and/or sequence of the peptides P5, its specific fragments exemplified by peptides P5-1 and P5-1a, or the corresponding active mutants as defined above. The tridimensional structures of OX40L and OX40R, as separate molecules or as a
20 complex, have not been solved yet but the disclosure provided in this patent application, once that this information will be available, will allow to study the interaction between OX40L and OX40R with greater efficacy using these and other simulation technologies (Cochran A et al., 2001; Kraemer-Pecore CM et al., 2001). Such computer-assisted analysis can be exploited to develop improved peptide or non-

peptide mimetic drugs in the form of synthetic organic molecules or peptides (for example, having between 4 and 20 amino acid). Once that these compounds have been screened and found to be capable of binding OX40R and competing with OX40L, it will then be assessed their utility using cell or animal models.

5 Useful conjugates or complexes of the OX40R binding agents of the present invention can be generated, using molecules and methods known in the art (as shown for anti-OX40R antibodies in WO 95/21251) to improve their detection (with radioactive or fluorescent labels, biotin), their therapeutic efficacy (with cytotoxic agents), and/or their delivery, with polyethylene glycol and other natural or synthetic polymers (Pillai O
10 and Panchagnula R, 2001).

The peptides P5, its specific fragments exemplified by peptides P5-1 and P5-1a, the corresponding active mutants, and the fusion proteins containing them, can be prepared by known chemical synthesis or by recombinant DNA-based techniques.

Another object of the invention are the nucleic acids encoding for the OX40R
15 binding agents of the invention, including nucleotide sequences substantially the same.

"Nucleotide sequences substantially the same" includes all other nucleic acid sequences that, by virtue of the degeneracy of the genetic code, also code for the given amino acid sequences.

The invention also includes vectors of viral or plasmid origin which allows the
20 expression of the nucleic acid encoding for the OX40R binding agents of the Invention and prokaryotic or eukaryotic host cells transformed with such vectors. A stable cell line substantially enriched in these transformed cells can be isolated, also on the basis of the expression features of the OX40R binding agent, which can be secreted or expressed on the membrane surface, for example on human B cells.

OX40R binding agents of the invention can be produced by method wherein the host cells above described, are cultured in an appropriate culture media and the OX40R binding agent is collected.

The DNA sequence coding for the proteins of the invention can be inserted and
5 ligated into a suitable vector. Once formed, the expression vector is introduced into a suitable host cell, which then expresses the vector(s) to yield the desired protein.

Expression of any of the recombinant proteins of the invention as mentioned herein can be effected in eukaryotic cells (e.g. yeasts, insect or mammalian cells) or prokaryotic cells, using the appropriate expression vectors. Any method known in the
10 art can be employed.

For example the DNA molecules coding for the proteins obtained by any of the above methods are inserted into appropriately constructed expression vectors by techniques well known in the art. Double stranded cDNA is linked to plasmid vectors by homopolymeric tailing or by restriction linking involving the use of synthetic DNA linkers
15 or blunt-ended ligation techniques: DNA ligases are used to join the DNA molecules, and undesirable joining is avoided by treatment with alkaline phosphatase.

In order to be capable of expressing the desired protein, an expression vector should also comprise specific nucleotide sequences containing transcriptional and translational regulatory information linked to the DNA coding the desired protein in such
20 a way as to permit gene expression and production of the protein. First in order for the gene to be transcribed, it must be preceded by a promoter recognizable by RNA polymerase, to which the polymerase binds and thus initiates the transcription process. There are a variety of such promoters in use, which work with different efficiencies (strong and weak promoters).

For Eukaryotic hosts, different transcriptional and translational regulatory sequences may be employed, depending on the nature of the host. They may be derived from viral sources, such as adenovirus, bovine papilloma virus, Simian virus or the like, where the regulatory signals are associated with a particular gene which has a high level of expression. Examples are the TK promoter of the Herpes virus, the SV40 early promoter, the yeast gal4 gene promoter, etc. Transcriptional initiation regulatory signals may be selected which allow for repression and activation, so that expression of the genes can be modulated.

The DNA molecule comprising the nucleotide sequence coding for the protein of the invention is inserted into vector(s), having the operably linked transcriptional and translational regulatory signals, which is capable of integrating the desired gene sequences into the host cell.

The cells that have been stably transformed by the introduced DNA can be selected by also introducing one or more markers allowing for selection of host cells containing the expression vector. The marker may also provide for phototrophy to an auxotrophic host, biocide resistance, e.g. antibiotics, or heavy metals such as copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection.

Additional elements of the vectors may also be useful for obtaining an optimal production of proteins of the invention, in particular for selecting a particular cell containing plasmid or viral vector: the ease with which recipient cells, that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host;

and whether it is desirable to be able to “shuttle” the vector between host cells of different species.

Once the vector(s) or DNA sequence containing the construct(s) has been prepared for expression the DNA construct(s) may be introduced into an appropriate
5 host cell by any of a variety of suitable means: transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc.

Host cells may be either prokaryotic or eukaryotic. Preferred are eukaryotic hosts, e.g. mammalian cells, such as human, monkey, mouse, and Chinese Hamster Ovary
10 (CHO) cells, because they provide post-translational modifications to protein molecules, including correct folding or glycosylation at correct sites. Also yeast cells can carry out post-translational peptide modifications including glycosylation. A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number of plasmids that can be utilized for production of the desired proteins in
15 yeast. Yeast recognizes leader sequences on cloned mammalian gene products and secretes peptides bearing leader sequences (i.e., pre-peptides).

After the introduction of the vector(s), the host cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the desired proteins.

20 These objects of the invention can be achieved by combining the disclosure provided by the present patent application on recombinant OX40R binding agents, with the knowledge of common molecular biology techniques. Many reviews (Makrides SC, 1999) and books provides teachings on how to clone and produce recombinant proteins using vectors and Prokaryotic or Eukaryotic host cells, such as some titles in

the series "A Practical Approach" published by Oxford University Press ("DNA Cloning 2: Expression Systems", 1995; "DNA Cloning 4: Mammalian Systems", 1996; "Protein Expression", 1999; "Protein Purification Techniques", 2001).

Examples of chemical synthesis technologies, which are more indicated for producing the OX40R binding agent of the Invention when they are in the form of peptide or peptide mimetics, are solid phase synthesis and liquid phase synthesis. As a solid phase synthesis, for example, the amino acid corresponding to the C-terminus of the peptide to be synthesized is bound to a support which is insoluble in organic solvents, and by alternate repetition of reactions, one wherein amino acids with their amino groups and side chain functional groups protected with appropriate protective groups are condensed one by one in order from the C-terminus to the N-terminus, and one where the amino acids bound to the resin or the protective group of the amino groups of the peptides are released, the peptide chain is thus extended in this manner.

Solid phase synthesis methods are largely classified by the tBoc method and the Fmoc method, depending on the type of protective group used. Typically used protective groups include tBoc (t-butoxycarbonyl), Cl-Z (2-chlorobenzyloxycarbonyl), Br-Z (2-bromobenzyloxycarbonyl), Bzl (benzyl), Fmoc (9-fluorenylmethoxycarbonyl), Mbh (4,4'-dimethoxydibenzhydryl), Mtr (4-methoxy-2,3,6-trimethylbenzenesulphonyl), Trt (trityl), Tos (tosyl), Z (benzyloxycarbonyl) and Cl₂-Bzl (2,6-dichlorobenzyl) for the amino groups; NO₂ (nitro) and Pmc (2,2,5,7,8-pentamethylchromane-6-sulphonyl) for the guanidino groups; and tBu (t-butyl) for the hydroxyl groups). After synthesis of the desired peptide, it is subjected to the de-protection reaction and cut out from the solid support. Such peptide cutting reaction may be carried with hydrogen fluoride or trifluoromethane sulfonic acid for the Boc method, and with TFA for the Fmoc method.

The OX40R binding agents obtained by recombinant DNA or chemical synthesis technologies are finally subjected to one or more steps of purification. Purification can be carried out by any one of the methods known for this purpose, i.e. any conventional procedure involving extraction, precipitation, chromatography, electrophoresis, or the like. For example, HPLC (High Performance Liquid Chromatography) can be used. The elution can be carried using a water-acetonitrile-based solvent commonly employed for protein purification. The invention includes purified preparations of the OX40R binding agents of the invention. Purified preparations, as used herein, refers to the preparations which are at least 1%, preferably at least 5%, by dry weight of the compounds of the invention.

The compounds of the invention described above (proteins, peptides, organic compounds) can be as a medicament, being antagonists of human OX40L, and in view of the literature on the activity of OX40L as inducer of RANTES expression (Kotani A. et al., 2002), and antagonists of human RANTES.

The OX40R binding agents of the invention can be used as active ingredient in pharmaceutical compositions for the prophylaxis and/or treatment of autoimmune diseases, inflammation, or infection.

OX40R binding agent of the invention, once bound to OX40R, acts as antagonist of OX40L, the therapeutical potential of such molecule is in the prophylaxis and/or treatment of autoimmune diseases (e.g. inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis), inflammations or infections, where an inhibition of CD4⁺ T cells activation is beneficial. This latter effect can be also used for reducing the population of CD4⁺ T cells that express OX40R.

The present invention also provides pharmaceutical compositions for the prophylaxis and/or treatment of diseases related to CD4⁺ T cells, comprising one of the OX40R binding agents of the invention as active ingredient. These pharmaceutical compositions can be formulated in combination with pharmaceutically acceptable carriers, excipients, stabilizers, or diluents. Depending on the properties of the agent, the pharmaceutical composition can be useful for diseases related to CD4⁺ T cells such as autoimmune diseases, inflammations, or infections.

Pharmaceutical compositions comprising the OX40R binding agents of the present invention include all compositions wherein said compound is contained in therapeutically effective amount, that is, an amount effective to achieve the medically desirable result in the treated animal. The pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers, biologically compatible vehicles suitable for administration to an animal (for example, physiological saline) and eventually comprising auxiliaries (like excipients, stabilizers or diluents) which facilitate the processing of the active compounds into preparations which can be used pharmaceutically.

The pharmaceutical compositions may be formulated in any acceptable way to meet the needs of the mode of administration. The use of biomaterials and other polymers for drug delivery, as well the different techniques and models to validate a specific mode of administration, are disclosed in literature (Luo B and Prestwich GD, 2001; Cleland JL et al., 2001). Modifications of the compounds of the invention to improve penetration of the blood-brain barrier would also be useful. Other methods of biomimetic transport and rational drug delivery in the field of transvascular drug delivery are known in the art (Ranney DF, 2000).

Any accepted mode of administration can be used and determined by those skilled in the art. For example, administration may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, oral, or buccal routes. Parenteral administration can be by bolus injection or by gradual perfusion over time. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions, which may contain auxiliary agents or excipients known in the art, and can be prepared according to routine methods. In addition, suspension of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions that may contain substances increasing the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Pharmaceutical compositions include suitable solutions for administration by injection, and contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound together with the excipient. Compositions which can be administered rectally include suppositories.

It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The dosage will be tailored to the individual subject, as is understood and determinable by one of skill in the art. The total dose required for each treatment may be administered by multiple doses or in a single dose. The pharmaceutical composition of the present invention may be administered

alone or in conjunction with other therapeutics directed to the condition, or directed to other symptoms of the condition. Usually a daily dosage of active ingredient is comprised between 0.01 to 100 milligrams per kilogram of body weight.

The compounds of the present invention may be administered to the patient
5 intravenously in a pharmaceutically acceptable carrier such as physiological saline. Standard methods for intracellular delivery of peptides can be used, e.g. delivery via liposomes. Such methods are well known to those of ordinary skill in the art. The formulations of this invention are useful for parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal.

10 As well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.

The OX40R binding agents of the present Invention can be used for the
15 detection of the extracellular domain of OX40R protein, as membrane-bound or a soluble protein. Obviously this use can be extended to the detection of activated CD4⁺ T cells expressing OX40R protein.

The method of detections based on these uses comprises a first step in which a sample is contacted with the agents or the cells, and a second step in which the
20 interaction between the extracellular domain of OX40R protein is detected directly (by the means of any label associated to the agent or the cell, as described before) or indirectly (by the means of the effects of this binding on the OX40R protein or the OX40R-expressing cell, for example), in order to indicate the presence of these elements.

The agent or the cells can be immobilized, before or after being put in contact with the sample, onto supports which allow not only the detection but also the purification, and / or the concentration of the OX40R extracellular domain, as membrane-bound or a soluble protein, or OX40R-expressing cells. These supports can
5 be consequently used in methods for the detection, the purification, and/or the concentration of OX40R extracellular domain, as membrane-bound or a soluble protein, or OX40R-expressing cells in a sample by contacting said sample with the supports, or with cells expressing the OX40R binding agent of the present invention. This and the previously described detection methods can be used to diagnose a
10 condition associated to decreased or increased presence of CD4⁺ T cells or of soluble OX40R protein.

he OX40R binding agent of the present invention, or the cells expressing them, can be administered in methods for the prophylaxis and/or treatment of autoimmune diseases, inflammations, or infections.

15 The present invention also discloses screening assay for the determination of the nature and the activity of compounds, as provided in Examples of the present patent application, inhibiting OX40R-OX40L interactions comprising:

- a) Forming a sample comprising the following elements:
- i. An element constituting the OX40R binding agent, chosen amongst the
20 compounds, the cells, and the supports described in the present invention;
 - ii. An element constituting the OX40R moiety, chosen amongst a protein comprising the extracellular domain of OX40R, a cell line expressing

OX40R extracellular domain on its surface, and a cell line secreting extracellular domain of OX40R; and

iii. The compound(s) to be tested as inhibitor(s) of OX40R-OX40L interaction.

5 b) Detecting, directly or indirectly, the effect of the compounds (iii) on the interactions between the elements (i) and (ii).

c) Comparing the effect detected in (b) amongst samples different in terms of quality and / or quantity of the elements of (a).

10 The support disclosed above represents a preferable element since those kinds of screening are more efficient and quick by using an binding element immobilized on supports like plastic microtiter plate or beads.

15 The present invention also provides novel kits comprising the OX40R binding agents, cells expressing them, or supports comprising them, for detecting extracellular domain of OX40R protein (as membrane-bound or a soluble protein) or activated CD4⁺ T cells, allowing also the diagnosis of a condition due to a decreased or increased presence of CD4⁺ T cells or of soluble OX40R protein in a sample obtained from a patient.

20 Finally, the present invention also provides a kit for screening compounds inhibiting the interaction of a protein ligand with a membrane-associated protein, comprising the extracellular portion of the membrane-associated protein and the protein ligand as fusion proteins having different tag sequences.

All references cited herein are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also

entirely incorporated by reference. Reference to known method steps, conventional method steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

Once understood the features of the methods and products disclosed in present application, the necessity and kind of additional steps can be easily deduced by reviewing prior art, as well as the non-limiting following figures and examples describing the basic details and some applications of the invention.

EXAMPLES

Example 1: Experimental design for detecting OX40L-OX40R interactions using an AlphaScreen™-based competition assay.

Methods

Proteins

Human OX40R-IgG₁ fusion protein has been described previously (Godfrey et al., 1994). The recombinant protein was prepared by constructing a mammalian expression vector based on pCEP4 (Invitrogen) in which the cDNA encoding for the extracellular portion of human OX40R (amino acids 1-208 of SWISSPROT Acc. N° P43489) was in-frame fused to the 5' end of the cDNA encoding for the constant region of human IgG₁ (hinge region, CH2 and CH3; amino acids 98-330 of SWISSPROT Acc. N° P01857). Recombinant OX40R-IgG₁ is expressed as a secreted protein due to the signal sequence of OX40R.

HEK293-EBNA cells were transfected, using the calcium phosphate technique with the expression construct, which contains a selectable marker gene for

Hygromycin. Cells were seeded at a density of 2×10^5 cells/ml in growth medium (DMEM/F-12 (1:1) supplemented with 10% Fetal Bovine Serum and 4 mM L-glutamine; Sigma Chemicals). The following day, the medium was replaced by DMEM/F-12 (1:1) supplemented with 2% Fetal Bovine Serum and 4 mM L-glutamine. One hour later, 5 cells were transfected and incubated at 37°C in a humidified atmosphere containing 5% CO₂ for 4 hours, then medium was changed back to the growth medium containing 10% Fetal Bovine Serum. Two days post transfection, the selection agent (Hygromycin B; 300 µg/ml) was added to the medium. A clone correctly expressing OX40R-IgG₁ was isolated amongst the selected cells.

10 Recombinant OX40R-IgG was purified from the supernatant of a cell culture generated from the isolated clone. The supernatant was clarified by centrifugation (10 minutes at 500x g) and subsequently filtered using PVDF membranes of 0.45 and 0.22 micrometres pore size (Millipore). In parallel, the purification column, containing 38 ml resin on which recombinant protein G was immobilized (Pharmacia), was equilibrated 15 in loading buffer (0.1 M Tris, pH 7.0) using a Bio-Logic FPLC system (Biorad). After equilibration with 20 column-volumes (CV) of loading buffer, the sample was applied to the column at a flow rate of 1ml/min. The column was washed away with a 10 CV of loading buffer to eliminate protein bound non-specifically to the resin. OX40R-IgG₁ fusion protein, immobilized on the protein G via the IgG₁ moiety, was eluted by a step 20 gradient using a 0.1 Glycine/HCl (pH 3.0) elution buffer. The resulting fractions were directly neutralized with 1M Tris (pH 7.6) to prevent protein degradation in the acidic elution buffer. Finally, the fractions containing the OX40R- IgG₁ fusion protein were desalted using a Sephadex G25 column (Pharmacia) equilibrated in PBS (Phosphate Buffer Saline) and stored in aliquots at -80°C until being used for the assays.

Human OX40L-murine CD8 and anti-murine CD8 biotinylated antibodies are commercially available (Ancell), as well as Suramin (Sigma Chemicals). Recombinant human soluble OX40L was prepared as a fusion protein with Glutathione-S-Transferase (GST) in a Baculovirus Expression System (Gateway™, Invitrogen) by cloning the extracellular portion of OX40L fused to GST in a plasmid that was then used to transfect SF9 cells. Expression and purification were performed according to Manufacturer's instructions.

Alphascreen™ Assay

Alphascreen™ modified acceptor and donor beads were purchased (Biosignal Packard). OX40R-IgG₁ and OX40L-CD8 fusion proteins were immobilized, respectively, onto protein A-conjugated acceptor beads and, by the means of a biotinylated anti-CD8 antibody, onto streptavidin-conjugated donor beads.

The binding assay was performed using Costar® 384-well white polystyrene plates (Corning). Each well of a 384-well plate contained a reaction mix having a volume of 25 microliters. Each of the five components of the reaction mix (OX40R-IgG₁, OX40L-CD8, biotinylated anti-CD8, streptavidin-conjugated donor beads, and Protein A-conjugated acceptor beads) was added in a volume of 5 microliters. All dilutions were made in assay buffer (Phosphate Buffer Saline and 0.1% BSA), with or without dimethyl sulfoxide (DMSO).

In the standard assay, OX40-IgG₁ and OX40L-CD8 were incubated together for 30 minutes, and then biotinylated anti-CD8 antibody (10 nM) was added. Following another incubation period of 30 minutes, streptavidin donor beads (20 µg/ml) and Protein A acceptor beads (20 µg/ml) were added to each individual well. The plate was

counted 1 hour later using a Packard Fusion™ reader (Biosignal Packard) set at a read time of 1 second/well. Owing to the light sensitivity of the donor and acceptor beads, the experiments were carried out under blue light and all incubation periods were performed at room temperature. The plate was read at an excitation wavelength of 680
5 nanometers combined with a shorter emission wavelength of 520-620 nanometers.

Data analyses

All K_D , IC_{50} and EC_{50} values were calculated using Prism® software (Graphpad Software). The transformation of IC_{50} values into K_i values was performed using the
10 Cheng-Prusoff equation (Cheng YC and Prusoff WH, 1973).

Results

OX40L binding assays known in the literature include FACS-based analysis (Taylor L et al, 2002), or a Biacore™-based analysis (Al-Shamkhani A et al., 1997).
15 Being these techniques unsuitable for high throughput screenings, a more efficient system to establish the potential inhibiting properties of OX40L-derived peptides on the OX40R-OX40L interaction was set up by making use of a commercially available technology called Amplified Luminescent Proximity Homogeneous Assay Screen (Alphascreen™; Packard Bioscience), a method based on the Luminescent Oxygen
20 Channeling Immunoassay (LOCI; EP515194; Ullman E et al., 1994).

Briefly, AlphaScreen™ technology provides an easy and reliable determination of the effect of compounds on biomolecular interactions and activities, in particular for protein/protein interaction assays. AlphaScreen™ relies on the use of "Donor" and "Acceptor" polystyrene beads, each coated with a layer of hydrogel providing functional

groups for conjugation of a specific molecule. When a biological interaction between the immobilized molecules brings the beads into proximity, a cascade of chemical reactions is initiated to produce a greatly amplified signal. Upon laser excitation at 680 nanometers, a photosensitizer in the "Donor" bead converts ambient oxygen to a more excited singlet state. The excited singlet state oxygen molecules diffuse across a maximum distance of 200 nanometers before rapidly decaying. If an acceptor bead is in close proximity, these oxygen molecules react with a chemiluminescer (such as thioxene derivatives) contained in the acceptor beads to generate chemiluminescence. The activated fluorophores subsequently emit light at 520-620 nanometers. In the absence of a specific biological interaction, the singlet state oxygen molecules produced by the donor bead go undetected without the close proximity of the Acceptor bead. AlphaScreen™ technology allows the detection of interactions with affinities in the sub-nanomolar / micromolar range.

In the present case, the experimental set-up was first tested using only the basic binding partners, immobilized on AlphaScreen™ beads by making use of different affinity tags having a short biological linker that avoids the use of exogenous labeling groups. The signal should be detected only when streptavidin donor and Protein A acceptor beads are separated by a distance of less than 200 nm, by virtue of the complex formed by biotinylated anti-CD8 antibody OX40L-CD8, and OX40R-IgG₁ (Fig. 1). The IgG₁-tagged extracellular domain of OX40R was incubated with soluble OX40L-CD8, forming a complex. Owing to the relevant tags, this complex was able to couple to Protein A acceptor beads and, in the presence of a biotinylated anti-CD8 antibody, and to the streptavidin donor beads, generating an detectable Alphascreen™ signal. In the presence of a compound competing for the OX40L-OX40R interaction, the donor

and acceptor beads should no longer be in proximity and the signal should no longer be detected.

In the initial experiments performed to determine the feasibility of this assay, the Alphascreen™ signal was increased with the addition of OX40R-IgG₁ in a dose-dependent manner (Fig. 2A). The calculated EC₅₀ values ($-\log EC_{50} \pm \text{SEM}$, Standard Error of the Mean) were $7.7 \times 10^{-9} \text{ M}$ (8.11 ± 0.04) and $7.9 \times 10^{-9} \text{ M}$ (8.10 ± 0.01) using 5 or 10 nM OX40-IgG₁, respectively. The experiment was then repeated using a wider range of receptor concentrations (2.5–80 nM) in order to determine the optimal concentration to use for this binding assay. Seven concentrations were tested in total and results demonstrated that each concentration generated a dose-dependent increase of the Signal/Background (S/B) ratio in the Alphascreen™ signal following incubation with OX40L-CD8 (Fig. 2B). In all cases, there were no significant differences between the calculated EC₅₀ values, which remain in the nanomolar range.

Taking these results into account, further experiments were performed at a concentration of OX40R-IgG₁ (10 nM) and of OX40L-CD8 (40 nM) allowing a good S/B window to work with and also ensured that the assay would be cost-effective by using only a minimum concentration of these fusion proteins.

The K_D of OX40L-CD8 for OX40R-IgG₁ was then calculated by subtracting the signal due to non-specific binding, as determined in the presence of suramin (1 mM), a small molecule inhibiting the interactions TNF-like proteins with their receptors (Alzani R et al., 1995). Specific binding of OX40L-CD8 was saturable and of high affinity (Fig. 3), with a calculated K_D value of $20.7 \pm 5.2 \text{ nM}$. This is in agreement with literature values when binding affinity of OX40L-CD4 for OX40R was measured using a Biacore

sensor chip method (Al Shamkhani A et al., 1997) and, in general, similar to K_D values obtained for other members of the TNF receptor family for their respective ligands.

The ability of two known competitors of OX40L-OX40R interactions (untagged recombinant human soluble OX40L and suramin), which are themselves unable to generate an Alphascreen™ signal in this assay in absence of OX40L-CD8, to displace OX40L-CD8 from OX40R-IgG₁ was investigated. The displacement experiments were performed, taking into consideration the approximate K_D value, with a concentration of OX40L-CD8 (40 nM) that was 4 times greater than that of the OX40R-IgG₁ (10 nM). Increasing concentrations of OX40L (3 μM–0.1 pM) or suramin (1 mM –1 nM) were added to a reaction mixture also containing OX40-IgG₁ (10 nM) and OX40L-CD8 (40 nM). Both compounds compete for OX40L-CD8 binding in a dose-dependent manner, with resulting IC_{50} values ($-\log IC_{50} \pm SEM$) of 5.9×10^{-9} M (8.23 ± 0.35) and 7.9×10^{-5} M (4.10 ± 0.06), respectively (Fig. 4). These values can be transformed by the Cheng-Prusoff equation (Cheng, YC and Prusoff, WH, 1973) to K_i values of 2.0 nM for OX40L and 26.3 μM for suramin. This latter value for suramin is similar to reported values for inhibition of TNF-α binding to the TNF receptor (Gray PW et al., 1990).

Further optimization of the assay was made to better define the conditions for performing the assay. The assay was able to tolerate, without any loss in signal, a dimethyl sulfoxide (DMSO) concentration up to 1%. The assay can be performed efficiently by combining OX40-IgG₁, OX40L-CD8 and biotinylated anti-CD8 antibody into a first addition step, and combining streptavidin donor and Protein A acceptor beads in a second addition step, keeping a total incubation time of 60 minutes. Both mixtures can be prepared in advance to addition to the plate.

The AlphascreenTM technology above described, initially developed for detecting OX40L-derived peptide that competitively inhibited OX40L-OX40R interaction, would be suitable to screen also for any other selective small-molecule or peptide inhibitors of such interaction. Since this assay is homogeneous, highly sensitive, robust and suitable for automation in a 384-well format, the same approach is potentially adaptable to the development of biochemical screens for many other protein ligands that interact with membrane-associated proteins, simply by expressing the extracellular portion of the membrane-associated protein and the protein ligand as fusion proteins fusion protein with different tag sequence (IgG1 and CD8, respectively, in the present case).

Example 2: Identification of OX40L-derived peptides binding OX40R

Methods

Peptides

Peptides (10-31 amino acids) were synthesized at purity ranging between 85-97% by Epytop (France), and stored in lyophilized form at -20°C. The peptides were solubilised in 0.1 mM NaOH in PBS before use. The name, sequence, and the corresponding amino acids in human OX40L for each peptide is shown in Table III.

AlphascreenTM-based Competition Assay

The soluble components (OX40-IgG1, OX40L-CD8 and biotinylated anti-CD8 antibody) were mixed at the concentration described before for the competition assays with OX40L and suramin (Fig. 4), together with various concentrations of each peptide in a 5 microliter volume into a first addition step. The streptavidin donor and Protein A

acceptor beads were added 30 minutes later. The plates were incubated for 2 hours in the dark, at room temperature and with shaking, before reading at a long excitation wavelength of 680 nm combined with a shorter emission wavelength of 520-620 nanometers, as described in Example 1.

5

Fluorescence quenching Assay

The fluorescence quenching assay was performed as previously described (Golabek A et al., 2000). OX40R-IgG₁ (35 micrograms) was dissolved in 500 microliters of PBS and the fluorescence spectrum was recorded at 295-420 nanometers with an excitation wavelength of 290 nanometers using a spectrofluorimeter (Perkin Elmer LS50B) with the slits set at 5 nanometers. Fluorescence spectra of human OX40R-IgG₁ were then recorded in the presence of increasing concentrations (5-1000 nM) of P5 and P5-1 peptides after 15 minutes of equilibration. The fluorescence change at 336 nanometers was plotted versus peptide concentration and the resulting curves were analyzed by nonlinear regression fit with Prism® software (GraphPad).

15

Results

A series of partially overlapping peptides were designed on the sequence of extracellular domain of human OX40L (Fig. 5A; Table III), which corresponds to the amino acids 51-183 of the protein. In this area, two peptides were previously designed on the sequence of mouse OX40L for raising anti-OX40L antibodies (Stuber E and Strober W, 1996).

20

Using a first series of peptides in the Alphascreen™-based competition assay described in Example 1, it was possible to define a peptide (P5) capable to inhibit the

binding of OX40R to OX40L in the micromolar range (figure 5B), an affinity value which is pharmacologically relevant.

On the basis of the sequence of the P5 peptide, a second series of partially overlapping peptides were tested to further reduce this inhibiting molecule (figure 6A; Table III). The result of this sequential screening is that the region comprised between amino acids 94 and 124 of human OX40L (P5) is not a minimal region since a peptide corresponding to amino acids 107-116 (P5-1), is capable to inhibit the binding of OX40R to OX40L still in the micromolar range ($K_d \sim 10$ and 62 microMolar respectively). The other tested peptides showed no or hardly measurable effect on OX40R-OX40L interaction (figure 6B).

Since the P4 peptide, which contains the C-terminal six amino acids of P5-1 peptide, proved to bind OX40R very poorly, it can be also inferred that the N-terminal amino acids of P5-1 peptide, for example the sequence GYFSQ (peptide P5-1a; amino acids 107-111 in human OX40L; SEQ ID NO: 13), may represent a minimal peptide sequence functionally active as OX40R binding agent. When compared to the mouse OX40L-derived peptide P-OX-1 (Stuber E and Strober W, 1996), this peptide contains two non-conservative substitutions (Fig. 6A).

The sequences of P5 and P5-1 peptides identified in this example by competition assays allowed to identify structures in the OX40L which play an essential role in the OX40L-OX40R interaction, demonstrating that OX40L can be effectively competed by specific peptide sequences. These findings were not predictable from the analysis of the state of the art on the structure-activity relationship of these proteins, neither of other TNF / TNFR-like proteins, being the regions of contact between proteins

belonging to these families very diverse amongst the pairs of ligands and receptors (Bodmer JL et al., 2002).

The affinity of the peptides identified in Example 1 as inhibitor of OX40L-OX40R interaction was evaluated by fluorescence quenching spectroscopy, a technology
5 allowing such measurements in solution, under native conditions and without beads or other supports. This method is based on monitoring the changes in the intrinsic fluorescence of a protein (OX40R-IgG₁) upon its binding with another protein (P5 or P5-1). Incubation of OX40R-IgG₁ with increasing concentrations of P5 or P5-1 peptides caused a change of its intrinsic fluorescence in the form of an hyperbolic curve, when
10 the changes in OX40R-IgG₁ fluorescence were plotted against peptide P5 and P5-1 concentration (Figure 7A and 7B). Non-linear regression analysis of the data revealed an apparent dissociation constant for OX40R of $K_D \sim 7.9$ nM, and $K_D \sim 24.6$ nM for peptides P5 and P5-1, respectively. These values demonstrate a high affinity interaction between the OX40R-IgG₁ and the selected peptides, which can be therefore
15 used as OX40L antagonists.

The findings presented in this Example indicate that OX40R-OX40L interaction can be effectively inhibited by using specific OX40L-derived peptides which bind efficiently OX40R, providing novel opportunity for the development of drugs targeting the OX40R pathway and inhibiting aberrant or undesirable physiological events under
20 its control. These OX40R binding agents can be then further characterized as antagonist of OX40L in its interaction with OX40R using the animal and cell biology assay known in the art (WO 99/42585; Imura A et al., 1997; Nohara C et al., 2001; Pippig SD et al., 1999; Kotani A. et al., 2002), and further validated by testing other potential use-limiting side-effects in relevant models (Coleman RA et al., 2001).

TABLE I

Amino Acid	Synonymous Group	More Preferred Synonymous Groups
Ala	Gly, Thr, Pro, Ala, Ser	Gly, Ala
Arg	Asn, Lys, Gln, Arg, His	Arg, Lys, His
Asn	Glu, Asn, Asp, Gln	Asn, Gln
Asp	Glu, Asn, Asp, Gln	Asp, Glu
Cys	Ser, Thr, Cys	Cys
Gln	Glu, Asn, Asp, Gln	Asn, Gln
Glu	Glu, Asn, Asp, Gln	Asp, Glu
Gly	Ala, Thr, Pro, Ser, Gly	Gly, Ala
His	Asn, Lys, Gln, Arg, His	Arg, Lys, His
Ile	Phe, Ile, Val, Leu, Met	Ile, Val, Leu, Met
Leu	Phe, Ile, Val, Leu, Met	Ile, Val, Leu, Met
Lys	Asn, Lys, Gln, Arg, His	Arg, Lys, His
Met	Phe, Ile, Val, Leu, Met	Ile, Val, Leu, Met
Phe	Trp, Phe, Tyr	Tyr, Phe
Pro	Gly, Ala, Ser, Thr, Pro	Pro
Ser	Gly, Ala, Ser, Thr, Pro	Thr, Ser
Thr	Gly, Ala, Ser, Thr, Pro	Thr, Ser
Trp	Trp, Phe, Tyr	Trp
Tyr	Trp, Phe, Tyr	Phe, Tyr
Val	Met, Phe, Ile, Leu, Val	Met, Ile, Val, Leu

TABLE II

Amino Acid	Synonymous Group
Ser	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys
Arg	D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn
Leu	D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met
Pro	D-Pro, L-1-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine-4-carboxylic acid
Thr	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val
Ala	D-Ala, Gly, Aib, B-Ala, Acp, L-Cys, D-Cys
Val	D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met, AdaA, AdaG
Gly	Ala, D-Ala, Pro, D-Pro, Aib, .beta.-Ala, Acp
Ile	D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met
Phe	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, AdaA, AdaG, cis-3,4, or 5-phenylproline, Bpa, D-Bpa
Tyr	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His
Cys	D-Cys, S--Me--Cys, Met, D-Met, Thr, D-Thr
Gln	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp
Asn	D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln
Lys	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Asp	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln
Glu	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln
Met	D-Met, S--Me--Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val

TABLE III

Peptide name	Peptide sequence	Correspondance with human OX40L
P1 (SEQ ID NO:2)	VASLTYKDKVYLNVTDTNTSLDDFHVNGGEL	150-180
P2 (SEQ ID NO:3)	LDDFHVNGGELILIHQNPGEFCVL	160-183
P3 (SEQ ID NO:4)	VSHRYPRIQSIKVQFTEYKKEKGFILTSQ	52-80
P4 (SEQ ID NO:5)	EKGFILTSQKEDEIMKVQNNSVIINCDGFYL	72-102
P5 (SEQ ID NO:6)	IINCDGFYLISLKGYSQEVNISLHYQKDEE	94-124
P6 (SEQ ID NO:7)	HYQKDEEPLFQLKKRSVNSLMVASLTYKDK	118-148
P5-1 (SEQ ID NO:8)	GYFSQEVNIS	107-116
P5-2 (SEQ ID NO:9)	ISLHYQKDEE	107-124
P5-3 (SEQ ID NO:10)	GFYLI SLKGY	99-108
P5-4 (SEQ ID NO:11)	QEVNISLHYQ	111-120
P5-5 (SEQ ID NO:12)	IINCDGFYLI	94-103

REFERENCES

- Al Shamkhani A et al., J Biol Chem, 272: 5275-5282, 1997.
- Alzani R et al., Biochemistry, 34: 6344-6350, 1995.
- Bansal-Pakala P et al., Nat Med, 7: 907-912, 2001.
- 5 Bodmer JL et al., Trends Bioch Sci, 27: 19-26, 2002.
- Chen A et al., Immunity, 11: 689-698, 1999.
- Cheng YC and Prusoff WH, Biochem Pharmacol, 22: 3099-3108, 1973.
- Cleland JL et al., Curr Opin Biotechnol, 12: 212-219, 2001.
- Cochran A et al., Curr Opin Chem Biol, 5 : 654-659, 2001.
- 10 Coleman RA et al., Drug Disc Today, 6: 1116-1125, 2001.
- Constans A, The Scientist, 16: 37, 2002.
- Dougherty DA, Curr Opin Chem Biol, 4: 645-652, 2000.
- Godfrey WR et al., J Exp Med, 180: 757-762, 1994.
- Golabek A et al., Biophys J, 79: 1008-1015, 2000.
- 15 Golebiowski A et al., Curr Opin Drug Discov Devel, 4: 428-434, 2001.
- Gravestien L and Borst J, Semin Immunol, 10: 423-434, 1998.
- Gray PW et al., Proc Natl Acad Sci, 87: 7380-7384, 1990.
- Higgins LM et al., J Immunol, 162: 486-493, 1999.
- Hruby VJ and Balse PM, Curr Med Chem, 7: 945-970, 2000.
- 20 Imura A et al., Blood, 89: 2951-2958, 1997.
- Kim HO and Kahn M, Comb Chem High Throughput Screen, 3: 167-183, 2000.
- Kopf M et al., Immunity, 11: 699-708, 1999.
- Kotani A et al., Immunol Lett, 84: 1-7, 2002.
- Kraemer-Pecore CM et al., Cur Opin Chem Biol, 5: 690-695, 2001.

- Lowe CR et al., J Biochem Biophys Methods, 49: 561-574, 2001.
- Luo B and Prestwich GD, Exp Opin Ther Patents, 11: 1395-1410, 2001.
- Makrides SC, Protein Expr Purif, 17: 183-202, 1999.
- Miura S et al., Mol Cell Biol, 11: 1313-1325, 1991.
- 5 Murata K et al., J Exp Med, 191: 365-374, 2000.
- Murphy LR et al., Protein Eng, 13: 149-152, 2000.
- Nohara C et al., J Immunol, 166: 2108-2115, 2001.
- Pillai O and Panchagnula R, Cur Opin Chem Biol, 5: 447-451, 2001.
- Pippig SD et al., J Immunol, 163: 6520-6529, 1999.
- 10 Ranney DF, Biochem Pharmacol, 59: 105-114, 2000.
- Rogov SI and Nekrasov AN, Protein Eng, 14: 459-463, 2001.
- Sawyer TK, in "Structure Based Drug Design", edited by Veerapandian P, Marcel Dekker Inc., pg. 557-663, 1997.
- Stuber E and Strober W, J Exp Med, 183: 979-989, 1996.
- 15 Taylor L and Schwarz H, J Imm Methods, 255: 67-72, 2001.
- Taylor L et al, J Leuk Biol, 72: 522-529, 2002.
- Tsukada N et al., Blood, 95: 2434-2439, 2000.
- Ullman E et al., Proc Natl Acad Sci, 91: 5426-5430, 1994.
- Villain M et al., Chem Biol, 8: 673-9, 2001.
- 20 Weinberg A et al., Nat Med, 2:183-189, 1996.
- Weinberg A et al., J Immunol, 162: 1818-1826, 1999.
- Weinberg A, Trends Immunol, 23: 102-109, 2002.
- Yoshioka Y et al., Eur J Immunol, 30: 2815-2823, 2000.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An OX40R binding agent which is the peptide sequence corresponding to amino acids 94-124 of human OX40L, said peptide sequence being provided as SEQ ID No.6.

5

2. The OX40R binding agent which is a peptide sequence of human OX40L consisting of SEQ ID NO: 6, wherein one or more amino acids have been deleted, and comprising amino acids 107-116 of human OX40L, wherein amino acids 107-116 of human OX40L are provided as SEQ ID No.8.

10

3. The OX40R binding agent of claim 2 which is a peptide sequence corresponding to amino acids 107-116 of human OX40L, said peptide sequence being provided as SEQ ID No.8.

15

4. The OX40R binding agent which is an active mutant of peptides of claims 1 to 3, wherein one or more of the amino acids has been conservatively substituted.

5. An OX40R binding agent which is a peptide sequence consisting of amino acids 107-111 of human OX40L, said peptide sequence being provided as SEQ ID No.13.

20

6. An OX40R binding agent which is a peptide having the sequence corresponding to amino acids 107-111 of human OX40L, said peptide sequence being provided as SEQ ID NO.13 and wherein said peptide sequence is not SEQ ID NO.99 of WO 00/58494.

7. An OX40R binding agent which is a fusion polypeptide or peptide consisting of any one of the OX40R binding agents of claim 1 to 4, fused to an amino acid sequence belonging to a protein sequence other than human OX40L, mouse OX40L or rabbit OX40L.

5

8. The OX40R binding agent of claim 7, wherein the fusion polypeptide or peptide comprises the amino acid sequence belonging to one or more of the following protein sequences: membrane-bound proteins, extracellular domains of membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular
10 proteins, signal peptide-containing proteins, export signal-containing proteins.

9. An OX40R binding agent which is a precursor, salt, or derivative of an OX40R binding agent of claims 1 to 8.

15

10. An OX40R binding agent which is an active conjugate or complex of an OX40R binding agent of claims 1 to 9 with a molecule chosen amongst radioactive labels, biotin, fluorescent labels, cytotoxic agents, and drug delivery agents.

11. A nucleic acid encoding for an OX40R binding agent of claims 1 to 8

20

12. An expression vector of viral or plasmid origin which comprises the nucleic acid of claim 11.

13. A prokaryotic or eukaryotic host cell which comprises an expression vector according to claim 12.

14. An isolated stable cell line substantially enriched in cells of claim 13.

15. The cell line of claim 14 wherein the OX40R binding agent is secreted or expressed on the membrane surface.

16. A method of producing an OX40R binding agent of claims 1 to 8, comprising culturing cells of claims 13 to 15 and collecting said binding agent.

17. Purified preparations of the OX40R binding agents of claims 1 to 10.

18. Use of the OX40R binding agents of claims 1 to 10 as a medicament.

19. Use of the OX40R binding agents of claims 1 to 10 as antagonists of human OX40L.

20. Use of the OX40R binding agents of claims 1 to 10 as antagonists of human RANTES.

21. Use of the OX40R binding agent of claims 1 to 10 as active ingredients in pharmaceutical compositions for the prophylaxis and/or treatment of autoimmune diseases, inflammations, or infections.

22. A pharmaceutical composition for the prophylaxis and/or treatment of diseases related to CD4⁺ T cells, comprising a OX40R binding agent of claims 1 to 10 as active ingredient.

5

23. The pharmaceutical composition of claim 22, in combination with pharmaceutically acceptable carriers, excipients, stabilizers, and/or diluents.

10

24 The pharmaceutical compositions of claim 22 or 23, wherein the diseases related to CD4⁺ T cells are transplant autoimmune diseases, inflammations, or infections.

15

25. Use of the OX40R binding agents of claims 1 to 10 or of the cells of claims 13 to 15 for the detection of the extracellular domain of OX40R protein as membrane-bound or a soluble protein.

26. Use of the OX40R binding agents of claims 1 to 10 or of the cells of claims 13 to 15 for the detection of activated CD4⁺ T cells.

20

27. Supports for the detection, the purification, and/or the concentration of OX40R extracellular domain, as membrane-bound or a soluble protein, or of activated CD4⁺ T cells, said supports having an OX40R binding agent of claims 1 to 10 in an immobilized form.

28. Methods for the detection, the purification, and/or the concentration of OX40R extracellular domain, as membrane-bound or a soluble protein, or of activated CD4⁺ T cells in a sample, said method comprising contacting said sample with the supports of claim 27 or with the cells of claims 13 to 15.

5

29. A method of claim 28, wherein the method is used to diagnose a condition associated to decreased or increased presence of CD4⁺ T cells or of soluble OX40R protein.

10 30. Methods for the prophylaxis and/or treatment of autoimmune diseases, inflammations, or infections comprising the administration of an OX40R binding agent of claims 1 to 10 or of the cells of claims 13 to 15.

31. A screening assay for the determination of the nature and the activity of
15 compounds modulating OX40R-OX40L interactions comprising:

a) Forming a sample comprising the following elements:

i. An element constituting the OX40R binding agent, chosen amongst the compounds of claims 1 to 10, the cells of claims 13 to 15, and the supports of claim 27;

20 ii. An element constituting the OX40R moiety, chosen amongst a protein comprising the extracellular domain of OX40R, a cell line expressing OX40R extracellular domain on its surface, and a cell line secreting extracellular domain of OX40R; and

iii. The compound(s) to be tested as modulator(s) of OX40R-OX40L interactions.

b) Detecting, directly or indirectly, the effect of the compounds (iii) on the interactions between the elements (i) and (ii);

5 c) Comparing the effect detected in (b) amongst samples different in terms of quality and/or quantity of the elements of (a).

10 32. A kit for detecting extracellular domain of OX40R protein or activated CD4⁺ T-cells which comprises an OX40R binding agent of claims 1 to 10, a cell of claims 13 to 15, or a support of claim 27.

15 33. A kit of claim 32 for the diagnosis of a condition due to a decreased or increased presence of CD4⁺ T cells or of soluble OX40R protein in a sample obtained from a patient.

Figure 1





Figure 2

A)



B)




Figure 3




Figure 4





Figure 5

A)



B)






Figure 7

A)



B)



SEQUENCE LISTING

<110> Applied Reasearch Systems ARS holding

<120> NOVEL OX40R BINDING AGENTS

<130> W0498

<160> 15

<170> PatentIn version 3.0

<210> 1

<211> 183

<212> PRT

<213> Homo sapiens

<400> 1

```

Met Glu Arg Val Gln Pro Leu Glu Glu Asn Val Gly Asn Ala Ala Arg
1      5      10
Pro Arg Phe Glu Arg Asn Lys Leu Leu Leu Val Ala Ser Val Ile Gln
20     25     30
Gly Leu Gly Leu Leu Leu Cys Phe Thr Tyr Ile Cys Leu His Phe Ser
35     40     45
Ala Leu Gln Val Ser His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val
50     55     60
Gln Phe Thr Glu Tyr Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln
65     70     75     80
Lys Glu Asp Glu Ile Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn
85     90     95
Cys Asp Gly Phe Tyr Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu
100    105    110
Val Asn Ile Ser Leu His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln
115    120    125
Leu Lys Lys Val Arg Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr
130    135    140
Tyr Lys Asp Lys Val Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu
145    150    155    160
Asp Asp Phe His Val Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn
165    170    175

```

Pro Gly Glu Phe Cys Val Leu
180

<210> 2

<211> 31

<212> PRT

<213> synthetic construct

<400> 2

Val Ala Ser Leu Thr Tyr Lys Asp Lys Val Tyr Leu Asn Val Thr Thr
1 5 10 15
Asp Asn Thr Ser Leu Asp Asp Phe His Val Asn Gly Gly Glu Leu
20 25 30

<210> 3

<211> 24

<212> PRT

<213> synthetic construct

<400> 3

Leu Asp Asp Phe His Val Asn Gly Gly Glu Leu Ile Leu Ile His Gln
1 5 10 15
Asn Pro Gly Glu Phe Cys Val Leu
20

<210> 4

<211> 29

<212> PRT

<213> synthetic construct

<400> 4

Val Ser His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr
1 5 10 15
Glu Tyr Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln
20 25

<210> 5

<211> 31

<212> PRT

<213> synthetic construct

<400> 5

Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile Met Lys
 1 5 10 15

Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr Leu
 20 25 30

<210> 6

<211> 31

<212> PRT

<213> synthetic construct

<400> 6

Ile Ile Asn Cys Asp Gly Phe Tyr Leu Ile Ser Leu Lys Gly Tyr Phe
 1 5 10 15

Ser Gln Glu Val Asn Ile Ser Leu His Tyr Gln Lys Asp Glu Glu
 20 25 30

<210> 7

<211> 30

<212> PRT

<213> synthetic construct

<400> 7

His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Arg Ser
 1 5 10 15

Val Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys
 20 25 30

<210> 8

<211> 10

<212> PRT

<213> synthetic construct

<400> 8

Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser
 1 5 10

<210> 9

<211> 10

<212> PRT

<213> synthetic construct

<400> 9

Ile Ser Leu His Tyr Gln Lys Asp Glu Glu
1 5 10

<210> 10

<211> 10

<212> PRT

<213> synthetic construct

<400> 10

Gly Phe Tyr Leu Ile Ser Leu Lys Gly Tyr
1 5 10

<210> 11

<211> 10

<212> PRT

<213> synthetic construct

<400> 11

Gln Glu Val Asn Ile Ser Leu His Tyr Gln
1 5 10

<210> 12

<211> 10

<212> PRT

<213> synthetic construct

<400> 12

Ile Ile Asn Cys Asp Gly Phe Tyr Leu Ile
1 5 10

<210> 13

<211> 5

<212> PRT

<213> synthetic construct

<400> 13

Gly Tyr Phe Ser Gln
1 5

<210> 14

<211> 18

<212> PRT

<213> synthetic construct

<400> 14

Leu Lys Gly Ser Phe Phe Gln Glu Val Lys Ile Asp Leu His Phe Arg
1 5 10 15

Glu Asp
20

<210> 15

<211> 18

<212> PRT

<213> synthetic construct

<400> 15

Ala Phe Lys Asp Lys Val Tyr Leu Thr Val Asn Ala Pro Asp Thr Leu
1 5 10 15

Cys Glu
20